AUTHOR=Loaeza-Reyes Karen Julissa , Zenteno Edgar , Ramírez-Hernández Eleazar , Salinas-Marin Roberta , Moreno-Rodríguez Adriana , Torres-Rosas Rafael , Argueta-Figueroa Liliana , Fernández-Rojas Berenice , Pina-Canseco Socorro , Acevedo-Mascarúa Alfonso E. , Hernández-Antonio Alicia , Pérez-Cervera Yobana TITLE=The modulation of the hexosamine biosynthetic pathway impacts the localization of CD36 in macrophages JOURNAL=Acta Biochimica Polonica VOLUME=71 YEAR=2024 URL=https://www.frontierspartnerships.org/journals/acta-biochimica-polonica/articles/10.3389/abp.2024.13004 DOI=10.3389/abp.2024.13004 ISSN=1734-154X ABSTRACT=

CD36 is a type 2 cell surface scavenger receptor expressed in various tissues. In macrophages, CD36 recognizes oxidized low-density lipoprotein (ox-LDL), which promotes the formation of foam cells, the first step toward an atherosclerotic arterial lesion. CD36 possesses a variety of posttranslational modifications, among them N-glycosylation and O-GlcNAc modification. Some of the roles of these modifications on CD36 are known, such as N-linked glycosylation, which provides proper folding and trafficking to the plasma membrane in the human embryonic kidney. This study aimed to determine whether variations in the availability of UDP-GlcNAc could impact Rab-5-mediated endocytic trafficking and, therefore, the cellular localization of CD36. These preliminary results suggest that the availability of the substrate UDP-GlcNAc, modulated in response to treatment with Thiamet G (TMG), OSMI-1 (O-GlcNAcylation enzymes modulators) or Azaserine (HBP modulator), influences the localization of CD36 in J774 macrophages, and the endocytic trafficking as evidenced by the regulatory protein Rab-5, between the plasma membrane and the cytoplasm.